Disease Landscape and Forecast Insights

Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The…

With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…

Patients with type 2 diabetes (T2D) and nephropathy, also known as diabetic nephropathy (DN), are at significant risk of developing end-stage renal disease (ESRD), a condition associated with…

Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…

Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…

Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers…

First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and  an oral diuretic. Second- or third-line treatments are…

The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The…

A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy including excessive daytime sleepiness and cataplexy.  Our Treatment Algorithms research…

The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity…

Hyperkalemia, a condition of elevated serum potassium, arises from disturbances to potassium homeostasis within the body. Among key populations, including patients with kidney disorders and/or HF,…

Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have…